Celgene moves higher on better than expected Q4 results
Celgene Corporation (CELG) is up 0.7% Thursday morning. The company reported adjusted Q4 earnings per share of $2.00, topping the $1.95 consensus. Celgene posted revenue of $3.48 billion versus the $3.47 billion estimate.
Celgene Corporation (CELG) is a biotech company.
Helmerich & Payne, Inc. (HP) and Celgene Corporation (CELG) top the list of other companies with positive news today, while Alaska Air Group, Inc. (ALK) and Ford Motor Company (F) top the list of companies with negative news.
Already a member?
Login to see your Morning News Leader Trade Idea.
Not yet a member?
You can receive four timely bull-put credit spreads each market day by joining our InvestorsKeyhole Daily Trade Alerts Service. Our analysts scour the news looking for unusual options activity, how insiders are trading, and breaking news, and publish trades accordingly.
Become A Member
About Celgene Corporation
Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U.S. in 2014. Recent acquisitions of Juno and Impact bring additional drugs for Celgene's blood cancer pipeline.